Methods of treatment using 3-desoxy vitamin D3 analogs

Details Methods of treatment using 3-desoxy vitamin D3 analogs Methods of treatment using 3-desoxy vitamin D3 analogs

2002-09-18

2009-02-17

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

C552S653000

Reexamination Certificate

active

07491711

ABSTRACT:
The present invention provides a method for treating osteoporosis, hyperparathyroidism or an autoimmune disease in a patient by administering to the patient a 3-desoxy vitamin D3analog of the formula:a prodrug or a salt thereof, where the dotted line, R1, R2, R3, R4and L are those defined herein. The present invention also provides methods for producing 3-desoxy vitamin D3analog of Formula I.

REFERENCES:
patent: 4225596 (1980-09-01), DeLuca
patent: 4264512 (1981-04-01), Okamura et al.
patent: 5484782 (1996-01-01), DeLuca et al.
patent: 5585368 (1996-12-01), Steinmeyer et al.
patent: 6372731 (2002-04-01), Kirsch et al.
patent: 6559138 (2003-05-01), Uskokovic
Qaqish et al. “Bone disorders associated with the human immunodeficiency virus” 2004, Pharmacotherapy, 24(10), 1331-46.
Zamboni et al. “Association of osteopetrosis and vitamin D-resistant rickets” 1977, Helv. Paediatr. Acta., 32(4-5), 363-8.
Okamura et al. “Vitamin D and its analogs” 1975, Biochemical and Biophysical Research Communications, 65(1), 24-30.
Koike, et al., “20-Cyclopropyl-cholecalciferol Vitamin D3 Analogs,”Anticancer Research, (1999) pp. 1689-1697, vol. 19:(3A).
Uskokovic, et al., “The 16-ene Analogs of 1,25- Dihydroxycholecalciferol. Synthesis and Biological Activity,” (1991) pp. 139-145 fromProceedings of the Eighth Workshop on Vitamin DParis, France.
A. Inzerillo et al., “Skeletal Fragility in the Elderly” inGeriatric Medicine4thEd., C. K. Cassel, Ed. in Chief, Springer, NY, 2003, p. 621-649.
P. D. Jardine & D. Thompson “Anti-Osteoporosis Agents” inAnnual Reports in Medicinal ChemistryChapter 22,1996 31:211.
A. Gray & I. R. Reid “Emerging and potential therapies for osteroposis”Expert Opin. Investig. Drugs2005 14(3):265-278 at 269.
J. Aerssens et al., “Effect of 1α-Vitamin D3on Bone Strength and Composition in Growing Rats with and without corticosteroid therapy”Calcif. Tissue Int.1994 55:443-450.
S. Pelarge et al., “Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats”Endocrinol 143(5): 1625.
A. I. Castillo et al. “Characterization of Vitamin D Receptor Ligands with Cell-Specific and Dissociated Activity”Mol. Endocrinol2006 20(12):3093-914.
V. N. Shankar et al. “Metabolism of a 20-methyl substituted series of Vitamin D analogs by cultured human cells: apparent reduction of 23-hydroxylation of the side chain by the 20-methyl group”Biochem. Pharmacol.2001 61:893-902.
R. Bouillon et al. “Structure-Function Relationships in the Vitamin D Endocrine System”Endocrin Rev.1994-5 16(2):200-256.
A. S. Lee et al., “3-Deoxy-3-thia-1α,25-dihydroxyvitamin D3and Its 1β Epimer: Synthesis and Biological Evaluation”J. Org. Chem.1992 57(14):3846-3854.
R. Marcus, “Agents Affecting Calcification and Bone Turnover”. InGoodman&Gilman's The Pharmacological Basis of Therapeutics,10thEd.; J. G. Hardman & L. E. Limbird, Editors-in-Chief; McGraw-Hill, New York, 2001, p. 1725.
National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; Apr. 2003 37; http://www.guideline.gov/summary/summary.aspx?doc—id=3862&nbr=003073&string=osteoporosis).
F. Cosman, The Prevention and Treatment of Osteoporosis: A Review, Medscape General Medicine, http://ww.mwdscape.com/viewpoint/4011—pnt, p. 11.
S. Pelarg and G. H. Posner, “Vitamin D Analogs as Modulators of Vitamin D Receptor Action,”Curr. Top. Med. Chem.2003 3:1555-1572.
J. Bostrom et al., “Do Structurally Similar Ligands Bind in a Similar Fashion?”,J. Med. Chem.2006 49(23):6716-6725.
R. Bouillon et al., Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3,J. Bone Miner. Res.1993 8(8):1009-1015.
C. J. Rosen, “Osteoporosis” InConn's Current Therapy 2005, R. E Rakel and E. T. Bope, Eds; Elsevier Sanders, Philadelphia, Pa, 2005, p. 700.
Prous ScienceIntegrity Database Search.
PharmaProjects Database Search.

Affiliated with

Also associated with

Rating

Methods of treatment using 3-desoxy vitamin D3 analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment using 3-desoxy vitamin D3 analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using 3-desoxy vitamin D3 analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4122556